Results 11 to 20 of about 4,750,590 (259)

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase

Clinical and Applied Thrombosis/Hemostasis, 2023
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD, Adel Hajj Ali MD, Faiz Anwer MD, Raza Shahzad MD, Sandra Mazzoni DO, Louis Williams MD, Chakra Chaulagain MD, Betty Hamilton MD, Craig Sauter MD, Jack Khouri MD   +9 more
doaj   +1 more source

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival [PDF]

, 2011
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
Hatton, CSR, Taylor Steve, Taylor, Stephen, Taylor, S, Lawrie Charles H, Saunders, NJ, Steve Taylor, Pezzella Francesco, Saunders Nigel J, Tramonti, D, Lawrie, CH, Wainscoat James S, Kusec, R, Pezzella, F, Tramonti Daniela, Nigel J Saunders, Hatton Christian SR, Chen, XH, Hatton, CS, Charles H Lawrie, Rajko Kušec, Littlewood, T, Erica Ballabio, Deborah Hay, Timothy Littlewood, Chi, J, Jacqueline Boultwood, Boultwood Jacqueline, Kušec Rajko, Jianxiang Chi, Chen Xiao-He, James S Wainscoat, Ballabio, E, Ballabio Erica, Chi Jianxiang, Xiao-He Chen, Littlewood Timothy, Francesco Pezzella, Christian SR Hatton, Wainscoat, JS, Hay Deborah, Pezzella, Francesco, Boultwood, Jacqueline, Hay, D, Boultwood, J, Daniela Tramonti   +45 more
core   +1 more source

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

Cells, 2022
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje   +2 more
doaj   +1 more source

Second malignancies after multiple myeloma: from 1960s to 2010s. [PDF]

, 2012
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients ...
Kristinsson, Sigurdur Y., Turesson, I, Thomas, A, Mailankody, Sham, Korde, Neha, Kristinsson, Sigurdur Y, Turesson, Ingemar, Mailankody, S, Landgren, Ola, Korde, N, Thomas, Anish, Lund University., Landgren, Carl, Turesson, Ingemar,, Kristinsson, SY, Landgren, O   +15 more
core   +1 more source

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Haematologica, 2018
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass   +8 more
doaj   +1 more source

Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools

Diagnostics, 2020
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife, James F. Sanchez, Flavia Pichiorri   +2 more
doaj   +1 more source

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma [PDF]

, 2002
Melphalan is widely used as a preparative agent in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT). Although disease relapse is the major cause of death after a melphalan-conditioned autograft, the mechanism ...
Mahendra, P, Hochhauser, D, Hockhauser, D, Spanswick, VJ, Shankaranarayana, P, Mahendra, Premini, Hughes, RG, Craddock, Charles; id_orcid, Craddock, C, Sekhar, M, Hartley, JA, Spanswick, V   +11 more
core   +1 more source

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Experimental Hematology & Oncology, 2017
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson   +4 more
doaj   +1 more source

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology, 2023
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jamin Koo   +11 more
doaj   +1 more source